

EFFECTS OF THE "UNDETECTABLE = UNTRANSMITTABLE" ("U=U") EDUCATIONAL CAMPAIGN ON TREATMENT OUTCOMES AND PERCEPTIONS AMONG PEOPLE LIVING WITH HIV IN NORTH AMERICAN COUNTRIES

<u>Frank Spinelli</u>,¹ Bruce Richman,² Patricia de los Rios,³ Benjamin Young,¹ Marvelous Muchenje,³ Nicolas Van de Velde,⁴ Chinyere Okoli⁴

¹ViiV Healthcare, Research Triangle Park, NC, USA; ²Prevention Access Campaign, New York, NY, USA; ³ViiV Healthcare, Laval, QC, Canada; ⁴ViiV Healthcare, Brentford, UK



Disclosures

- Frank Spinelli, Patricia de los Rios, Benjamin Young, Marvelous Muchenje, Nicolas Van de Velde, and Chinyere Okoli are employees of ViiV Healthcare and may own stock in GlaxoSmithKline
- Bruce Richman is a consultant for ViiV Healthcare



UNAIDS Targets Guide the Global HIV Response

 At the end of 2020, 27.5 million people living with HIV (PLHIV) were accessing antiretroviral therapy (ART), accelerating attainment of the UNAIDS goal to end AIDS as a public health threat by 2030^{1,2}

2025 AIDS TARGETS³

People living with HIV and communities at risk at the center



1. UNAIDS. https://www.unaids.org/en/resources/fact-sheet. Accessed August 7, 2021. 2. UNAIDS. https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf. Accessed August 3, 2021. 3. UNAIDS. https://aidstargets2025.unaids.org/. Accessed August 9, 2021.



The "Undetectable = Untransmittable" Educational Campaign May Help Motivate PLHIV to Reach Undetectability

- The advocacy and educational campaign "Undetectable = Untransmittable" (U=U) began in 2016 to improve the quality of life for PLHIV, encourage treatment uptake and adherence, and reduce HIV-related stigma for PLHIV¹
- The key message behind U=U is that PLHIV who are on treatment and achieve and maintain viral suppression cannot transmit HIV to their sexual partner^{2a}
- Healthcare provider (HCP) discussions of U=U with PLHIV have been shown to be associated with favorable health outcomes such as lower odds of suboptimal adherence and higher odds of self-reported viral suppression, optimal sexual health, and sharing of HIV status²

Key Objectives:

- To identify if the campaign affected HCP communication of U=U in North American countries (Canada, Mexico, and the United States)
- To determine if positive health outcomes differed by U=U informed status or country

^aThe U=U campaign uses "viral suppression" and "undetectable" interchangeably to describe untransmittable HIV.

1. Prevention Access Campaign. https://www.preventionaccess.org/consensus. Accessed August 11, 2021.

2. Okoli et al. Sex Transm Infect. 2021;97:18-26.



The Positive Perspectives Survey Is a Multinational Study






25 countries N=2389

Age ≥18 years





Specific analysis population



Okoli et al. Sex Transm Infect. 2021;97:18-26.

Key measure

"My provider has told me about 'undetectable = untransmittable' (U=U)"



OR

Strongly agree

Outcome variables







Sharing of HIV status



Optimal adherence



Treatment perceptions




Selected Participant Characteristics

Characteristic	Canada (N=120)	Mexico (N=63)	United States (N=400)
Age, n (%)			
≥50 y	24 (20)	15 (24)	122 (30)
Sex, n (%)			
Women	31 (26)	9 (14)	88 (22)
Men	87 (72)	51 (81)	306 (76)
Other ^a	2 (2)	3 (5)	6 (2)
Orientation, n (%)			
Homosexual	70 (58)	42 (67)	179 (45)
Heterosexual	33 (28)	14 (22)	180 (45)
Other ^b	17 (14)	7 (11)	41 (10)
Location of PLHIV, n (%)			
Metropolitan	50 (42)	48 (76)	170 (42)
Non-metropolitan	70 (58)	15 (24)	230 (58)
Year of diagnosis, n (%)			
≥2017	37 (31)	18 (29)	134 (34)
HCP has informed them of U=U, %	55.8	60.3	70.8

^aOther sex includes non-binary and prefer not to say. ^bOther sexual orientation includes bisexual, asexual, pansexual, and prefer not to say.





Year of Diagnosis Did Not Significantly Affect the Proportion of PLHIV Who Reported Being Informed of U=U by an HCP





Prevalence of Optimal Adherence and Sharing of HIV Status With ≥1 Person Besides an HCP Was Highest in Mexico









Receipt of Information on U=U Varied Significantly by Sexual Orientation, Sex, and Location of Residence in the United States but Not in Canada or Mexico


Proportion of PLHIV reporting receipt of U=U





^aOther sex includes non-binary and prefer not to say. ^bOther sexual orientation includes bisexual, asexual, pansexual, and prefer not to say. ^{*}P<0.01.


In the United States, PLHIV Who Reported Being Informed of U=U by Their HCP Had More Favorable Health Outcomes Than Those Not Informed



*P<0.01.

Association Between Receipt of U=U Information and Treatment Perceptions Varied Across Countries

 In Mexico, the proportion of PLHIV open to taking nondaily oral ART as long as their viral load is suppressed was significantly higher among those not informed of U=U than those informed



^aAs long as their viral load is suppressed.

^{*}P<0.01.



Conclusions

- Year of diagnosis did not significantly affect the proportion of PLHIV who reported receipt of information on U=U from an HCP in any North American country
- Prevalence of optimal adherence and sharing of HIV status with ≥1 person besides an HCP was highest in Mexico
- Receipt of information on U=U varied significantly by sexual orientation, sex, and location of residence in the United States but not in Canada or Mexico
- In the United States, PLHIV who reported being informed of U=U had more favorable health outcomes such as self-reported viral suppression, optimal sexual and mental health, and treatment satisfaction than those not informed
 - In the global Positive Perspectives survey analysis, PLHIV informed of U=U were significantly more likely to report optimal overall health than those not informed (P<0.001)¹
- Potential limitations include non-probabilistic sampling and use of web-based surveys, which may limit generalizability
- The association between the U=U discussion and health outcomes suggests opportunities exist to improve the healthcare experience of PLHIV
- Patient–HCP U=U discussions should be considered in care guidelines to help improve quality of life for PLHIV

1. Okoli et al. Sex Transm Infect. 2021;97:18-26.



Acknowledgments

- We thank everyone who has contributed to the success of this study, including all study participants
- This study was funded by ViiV Healthcare
- Contact Frank Spinelli at frank.a.spinelli@viivhealthcare.com with questions